Comparing Tirzepatide, Semaglutide, and Retatrutide: Next-Generation GLP-1 and Dual/Triple Agonists in Metabolic Research
IntroductionIn the rapidly advancing field of metabolic peptide therapeutics, GLP-1 receptor agonists have become foundational for treating type 2 diabetes and obesity. Recent innovations have introduced dual and triple receptor agonists, such as Tirzepatide and Retatrutide, which target multiple incretin pathways simultaneously. This blog compares these next-generation agents with the established GLP-1...